[go: up one dir, main page]

NO981810L - Compositions and Methods for Treating Bone Failure Conditions - Google Patents

Compositions and Methods for Treating Bone Failure Conditions

Info

Publication number
NO981810L
NO981810L NO981810A NO981810A NO981810L NO 981810 L NO981810 L NO 981810L NO 981810 A NO981810 A NO 981810A NO 981810 A NO981810 A NO 981810A NO 981810 L NO981810 L NO 981810L
Authority
NO
Norway
Prior art keywords
bone
ability
compositions
methods
failure conditions
Prior art date
Application number
NO981810A
Other languages
Norwegian (no)
Other versions
NO981810D0 (en
Inventor
Charles Petrie
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Original Assignee
Zymogenetics Inc
Osteoscreen Inc
Univ Texas At Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Osteoscreen Inc, Univ Texas At Austin filed Critical Zymogenetics Inc
Publication of NO981810D0 publication Critical patent/NO981810D0/en
Publication of NO981810L publication Critical patent/NO981810L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Forbindelser inneholdene to aromatiske systemer kovalentlig koblet gjennom en linker inneholdene en eller flere atomer, eller «linker» definert som inkluderende en kovalent binding per se for å plassere aromatiske systemer i en avstand på 1,5-lSÅ, som er effektive for behandling av tilstander assosiert med bensvikt. Forbindelsene kan bli administrert til virveldyr, mennesker alene eller i kombinasjon med ytterligere midler som fremmer benvekst eller som inhiberer benresorpsjon. De kan bli screenet for aktivitet før administrering ved å vurdere deres evne til å påvirke transkripsjon av et reportergen koblet til en promoter assosiert med et benmorfogenisk protein og/eller deres evne til å stimulere hodeskalleveksten i dyremodellsystemer.Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or "links" defined as including a covalent bond per se to place aromatic systems at a distance of 1.5-ISO, effective for treating conditions associated with bone failure. The compounds can be administered to vertebrates, humans alone, or in combination with additional agents that promote bone growth or that inhibit bone resorption. They may be screened for pre-administration activity by assessing their ability to influence transcription of a reporter gene linked to a promoter associated with a bone morphogenic protein and / or their ability to stimulate skull growth in animal model systems.

NO981810A 1995-10-23 1998-04-22 Compositions and Methods for Treating Bone Failure Conditions NO981810L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
PCT/US1996/017019 WO1997015308A1 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Publications (2)

Publication Number Publication Date
NO981810D0 NO981810D0 (en) 1998-04-22
NO981810L true NO981810L (en) 1998-06-22

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981810A NO981810L (en) 1995-10-23 1998-04-22 Compositions and Methods for Treating Bone Failure Conditions

Country Status (13)

Country Link
EP (1) EP0866710A4 (en)
JP (1) JP2000513324A (en)
KR (1) KR19990067010A (en)
CN (1) CN1201393A (en)
AU (1) AU706262B2 (en)
BR (1) BR9611210A (en)
CA (1) CA2235481A1 (en)
CZ (1) CZ115398A3 (en)
EA (1) EA199800393A1 (en)
HU (1) HUP9802319A3 (en)
NO (1) NO981810L (en)
PL (1) PL327617A1 (en)
WO (1) WO1997015308A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258822A1 (en) 1996-06-20 1997-12-24 Sean Kerwin Compounds and methods for providing pharmacologically active preparations and uses thereof
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (en) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Use of extracts from Cimicifuga racemosa and Belamcanda sinensis as an estrogen-like organ-selective drug without uterotropic effects
JP2000004882A (en) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk Human MP52 gene promoter and method for searching for useful substances using the same
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
SK5282001A3 (en) * 1998-11-06 2002-01-07 Knoll Gmbh Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (en) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
AU776933B2 (en) 1999-12-28 2004-09-23 Eisai R&D Management Co., Ltd. Heterocyclic compounds having sulfonamide groups
FR2806408B1 (en) * 2000-03-17 2002-10-11 Oreal COSMETIC COMPOSITION COMPRISING A DERIVATIVE OF FURANE- NAPHTOQUINONE, THEIR USE AS COLORING AGENT AND DERIVATIVES
DE50108588D1 (en) 2000-06-05 2006-02-02 Austria Wirtschaftsserv Gmbh Heterocyclic hydrazones as anti-cancer agents
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
AU2003284492A1 (en) 2002-12-16 2004-07-09 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
ATE551324T1 (en) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv QUINOLINE AMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTORS
MXPA06012333A (en) 2004-04-30 2007-01-17 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor.
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101641339B (en) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 Compounds for the prevention and treatment of cardiovascular diseases
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
KR101629356B1 (en) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 Methods of preparing quinazolinone derivatives
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
AU2010224523B2 (en) 2009-03-18 2014-05-08 Resverlogix Corp. Novel anti-inflammatory agents
MX374414B (en) 2009-04-22 2025-03-06 Resverlogix Corp NEW ANTI-INFLAMMATORY AGENTS.
SI2773354T1 (en) 2011-11-01 2019-08-30 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
US9388138B2 (en) 2012-07-18 2016-07-12 University College Dublin National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (en) * 2012-10-22 2013-02-27 暨南大学 Ethane bridged indole compound, synthetic method and application thereof
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CN105073744B (en) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 Novel heterocyclic compounds as bromodomain inhibitors
CN107530356A (en) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 Compositions and methods of treatment for treating complement-associated diseases
CN107019687B (en) * 2017-05-08 2020-10-27 上海市伤骨科研究所 Application of N- (4-chlorphenyl) -3-hydroxy-2-naphthamide compound
CN111116552B (en) * 2020-01-17 2022-10-11 河北科技大学 Quinazolinone compound and preparation method thereof
CN114469863B (en) * 2021-11-26 2023-09-26 南方医科大学南方医院 Sterol liposomes as pulp and dentine drug delivery systems
CN116650481B (en) * 2021-12-10 2024-06-14 中南大学湘雅医院 Aromatic compounds as activators of plexin protein-B2 and their use in preparing drugs for treating osteoporosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (en) * 1987-12-18 1998-03-09 武田薬品工業株式会社 Osteoporosis prevention and treatment agent
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JPH06192272A (en) * 1992-12-24 1994-07-12 Japan Tobacco Inc New triazolobenzothiadiazine and triazolobenzothiadiazepine derivative
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (en) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Malonic acid based matrix metalloproteinase inhibitors
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth

Also Published As

Publication number Publication date
NO981810D0 (en) 1998-04-22
CN1201393A (en) 1998-12-09
BR9611210A (en) 1999-12-28
HUP9802319A3 (en) 1999-12-28
PL327617A1 (en) 1998-12-21
KR19990067010A (en) 1999-08-16
EP0866710A4 (en) 2001-07-11
WO1997015308A1 (en) 1997-05-01
JP2000513324A (en) 2000-10-10
AU706262B2 (en) 1999-06-10
CZ115398A3 (en) 1998-12-16
EA199800393A1 (en) 1998-12-24
EP0866710A1 (en) 1998-09-30
CA2235481A1 (en) 1997-05-01
AU7471096A (en) 1997-05-15
HUP9802319A2 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
NO981810L (en) Compositions and Methods for Treating Bone Failure Conditions
NO20043411L (en) Substituted quinazolin-4-ylamine analogues
BR0010989A (en) Genetically modified plants and plant cells with increased activity of an amylosaccharide protein and a branching enzyme
PL328723A1 (en) Methods of and compositions for stimulating the growth of axons
BRPI0411319A (en) therapeutically active compounds and their use
WO2005009349A3 (en) Composition and method for treating neurological disorders
DK0861228T3 (en) Lipopolyamines as transfection agents as well as their pharmaceutical uses
MXPA02005510A (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation.
BR0011394A (en) Molecule, purified protein, isolated nucleic acid, recombinant cell, methods for producing a protein, for treating or preventing cancer and an immune disorder, and for activating or enhancing the immune response in an individual, non-human animal, plant or transgenic isolated cell, pharmaceutical composition and antibody
AP2002002596A0 (en) Piperazine and piperidine derivatives.
Ben-Hur Involvement of poly (ADP-ribose) in the radiation response of mammalian cells
ATE413179T1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL DEFICIENCY CONDITIONS
ATE184883T1 (en) MURAMYL COMPOUNDS FOR TREATING SEPTIC SHOCK
FI953369A7 (en) Pharmaceutical compositions for preventing and treating cancer and a method for their preparation
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
Yang et al. Kaempferol stimulates bone sialoprotein gene transcription and new bone formation
ATE289808T1 (en) CAROTEINOID-NICOTINAMIDE-ZINC COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
BR9812660A (en) Compositions and methods for treating respiratory disorders
WO2001082952A3 (en) USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
Steeves et al. Engines, Accelerators, and Brakes on Functional Spinal Cord Repair a
NO20010940D0 (en) TAN-1057 derivatives
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
NO985676L (en) Compounds with colchicine structure, their use as drugs and drugs
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application